Evidence map›Paper›PMID 38722418›Full record

ArticleWorld journal of urology2024

Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.

Tetsuya Shindo, Kohei Hashimoto, Keiko Fujino, Atsushi Takahashi, Hiroshi Hotta, Toshihiro Maeda, Yasuharu Kunishima, Fumimasa Fukuta, Naoki Ito, Atsushi Wanifuchi and 8 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tetsuya ShindoDepartment of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, 060-8543, Japan.
Kohei HashimotoDepartment of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, 060-8543, Japan. kohei@cj9.so-net.ne.jp.
Keiko FujinoDepartment of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, 060-8543, Japan.
Atsushi TakahashiDepartment of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan.
Hiroshi HottaDepartment of Urology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
Toshihiro MaedaDepartment of Urology, Oji General Hospital, Tomakomai, Japan.
Yasuharu KunishimaDepartment of Urology, Sunagawa City Medical Center, Sunagawa, Japan.
Fumimasa FukutaDepartment of Urology, Steel Memorial Muroran Hospital, Muroran, Japan.
Naoki ItoDepartment of Urology, NTT East Medical Center Sapporo, Sapporo, Japan.
Atsushi WanifuchiDepartment of Urology, Japanese Red Cross Kushiro Hospital, Kushiro, Japan.
Ryuichi KatoDepartment of Urology, Muroran City General Hospital, Muroran, Japan.
Manabu OkadaDepartment of Urology, Obihiro Kyokai Hospital, Obihiro, Japan.
Masanori MatsukawaDepartment of Urology, Takikawa Municipal Hospital, Takikawa, Japan.
Hiroki HoritaDepartment of Urology, Saiseikai Otaru Hospital, Otaru, Japan.
Akio TakayanagiDepartment of Urology, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan.
Ko KobayashiDepartment of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, 060-8543, Japan.
Toshiaki TanakaDepartment of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, 060-8543, Japan.
Naoya MasumoriDepartment of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, 060-8543, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo explore pre-treatment risk factors for overall survival (OS) in advanced urothelial carcinoma (UC) patients treated with first-line (1L) chemotherapy in sequential therapy (ST) era. Additionally, to evaluate the proportion of patients who were not able to undergo subsequent immune checkpoint inhibitor (ICI) therapy according to the subgroups stratified by the risk factors.

methodsA multicenter retrospective study was conducted. Metastatic or locally advanced UC patients treated between 2017 and 2022 were included. The Kaplan-Meier method with the log-rank test and multivariate Cox regression models were used to address OS.

resultsThree hundred and fourteen patients treated with 1L chemotherapy were included in the study and 57 (18.2%) patients were not able to proceed to subsequent ICI therapy. Pre-chemotherapy risk factors for OS in 314 patients were ECOG-PS 1 or more, having no primary site resection, C-reactive protein (CRP) level of 3 mg/dL or more, and non-cisplatin-based regimen. Patients having 3 or 4 risk factors had higher risk for not being able to receive ST (Mann-Whitney U test, P < 0.001). As risk factors for OS in 230 patients who were able to receive ST, having no primary site resection, a neutrophil to lymphocyte ratio of 3 or more, and the presence of liver metastasis were identified.

conclusionWe reported the risk factors for OS in advanced UC patients treated with 1L chemotherapy in ST era. Patients with high risk for OS may not be able to proceed to subsequent ICI therapy even in the ST era.

Indexed as

Carcinoma, Transitional CellAgedFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateUrinary Bladder NeoplasmsUrologic NeoplasmsImmune Checkpoint InhibitorsChemotherapyImmune checkpoint inhibitorOverall survivalSequential therapyUrothelial carcinoma

Identifiers

PMID38722418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.